Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe

Rgia A. Othman, Semone B. Myrie, David Mymin, Jean Baptiste Roullet, Andrea E. DeBarber, Robert D. Steiner, Peter J.H. Jones

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Objectives To assess the association between biomarkers of thyroid status and 5α-stanols in patients with sitosterolemia treated with ezetimibe (EZE). Study design Eight patients with sitosterolemia (16-56 years of age) were studied during 14 weeks off EZE therapy and 14 weeks on EZE (10 mg/day). Serum thyroid biomarkers (free triiodothyronine [FT3], free thyroxine [FT4], FT3/FT4 ratio, thyroid-stimulating hormone), 5α-stanols (sitostanol and cholestanol), and cholestanol precursors (total cholesterol and its synthesis marker lathosterol, and 7α-hydroxy-4-cholesten-3-one cholestenol) were measured at baseline and during the 14 weeks off EZE and on EZE. Results EZE increased FT3/FT4 (10% ± 4%; P =.02). EZE reduced plasma and red blood cells sitostanol (−38% ± 6% and −20% ± 4%; all P <.05) and cholestanol (−18% ± 6% and −13% ± 3%; all P <.05). The change in plasma cholestanol level on EZE inversely correlated with the change in FT3/FT4 (r = −0.86; P =.01). EZE lowered total cholesterol (P <.0001) and did not affect 7α-hydroxy-4-cholesten-3-one cholestanol. EZE increased (P <.0001) lathosterol initially, but the level was not sustained, resulting in similar levels at week 14 off EZE and on EZE. Conclusion In patients with STSL, 5α-stanols levels might be associated with thyroid function. EZE reduces circulating 5α-stanols while increasing FT3/FT4, implying increased conversion of T4 to T3, thus possibly improving thyroid hormone status. Trial registration ClinicalTrials.gov NCT01584206.

Original languageEnglish (US)
Pages (from-to)198-204.e1
JournalJournal of Pediatrics
Volume188
DOIs
StatePublished - Sep 2017

Keywords

  • 7α-hydroxy-4-cholesten-3-one
  • cholestanol
  • lathosterol
  • phytosterolemia
  • sitostanol
  • total cholesterol

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe'. Together they form a unique fingerprint.

  • Cite this

    Othman, R. A., Myrie, S. B., Mymin, D., Roullet, J. B., DeBarber, A. E., Steiner, R. D., & Jones, P. J. H. (2017). Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe. Journal of Pediatrics, 188, 198-204.e1. https://doi.org/10.1016/j.jpeds.2017.05.049